Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquir

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.5 OF THE IRISH TAKEOVER RULES
FOR IMMEDIATE RELEASE
Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near-term Inflection Points
Diversifies Revenue Base with Two Rapidly Growing Brands in Xeris' Gvoke® and Strongbridge's KEVEYIS®

Related Keywords

Ireland , New York , United States , District Of Columbia , State Of New York , Delaware , Dublin , Chicago , Illinois , America , Irish , Jeffreyw Sherman , Strongbridge Rsus , Andy Brimmer , Meagher Flom , Marten Steen , Joele Frank , Paulr Edick , Paul Edick , Allison Wey , Lindsay Rocco , Garheng Kong , Johnh Johnson , Strongbridge Biopharma , Wilkinson Brimmer Katcher , John Johnson , Development Pipeline , Xeris Party , Court Meeting Resolution , Registrar Of Companies , Strongbridge Us Inc , Nasdaq , Us Food Drug Administration Orange Book , Court Meeting , Arthur Cox , Xeris Biopharma Holding , Wells Mergersub Inc , Strongbridge Group , Milestone Payment In Xeris Biopharma Holdings , Xeris Pharmaceuticals Inc , Court Order , Articles Of Association , Health Cap , Health Partners , Qualification Organisation , Xeris Biopharma Holdings Directors , Drug Administration , European Commission , Xeris Biopharma Holdings Share , Exchange Commission , Xeris Biopharma Holdings Or Strongbridge , Xeris Biopharma Holdings Of Strongbridge , Corporate Authority , Goodwin Procter , High Court , Strongbridge Dublin , Party Or , Xeris Pharmaceuticals , Council Regulation Ec No , Relevant Authority , Twitter , Irish Registrar Of Companies , Takeover Panel , Court Order Of The High , United States Securities Exchange , Al Goodbody , Elixir Health Public Relations , Avenue Venture Opportunities Fund , Admission To Trading Of Xeris Biopharma Holdings , Xeris Biopharma Holdings , Irish Companies , Ecr Group , Xeris Biopharma Holdings Inc , Company The Directors In Section , Irish Takeover Panel , Avenue Venture Opportunity Fund , Corporate Communications , European Medicines Agency , Xeris Group , International Securities Identification Number , Xeris Shares , Strongbridge Shareholders , Biopharma Holdings Shares , Strongbridge Share , Strongbridge Shares , Xeris Biopharma Holdings Shares , Orange Book , Xeris Shareholders , Chief Executive Officer , Financial Benefits , Increased Revenue , Independent Xeris Directors , Xeris Share , Biopharma Holdings , Xeris Biopharma , Xeris Directors , Nasdaq Global Select Market , Strongbridge Directors , Transaction Agreement , Wells Mergersub , Effective Date , New Drug Application , European Medicines , Irish Takeover Rules , Vice President , Investor Relations , Wilkinson Brimmer , Securities Act , Scheme Document , Takeover Offer Document , Additional Information , Registration Statement , Joint Proxy Statement , Xeris Shareholder Meeting , Strongbridge Meetings , Joint Proxy , Xeri Annual Report , Proxy Statement , Annual Report , Irish Takeover , Independent Strongbridge , Independent Strongbridge Directors , Profit Forecast , Takeover Offer , Exchange Act , Share Consideration , Xeris Biopharma Holding Shares , Depository Trust Company , Milestone Payment , Strongbridge Shareholder , Xeris Board , Independent Xeris Director , Independent Strongbridge Director , Strongbridge Shareholder Approval , Xeris Shareholder Approval , Irish Registrar , European Economic Area , Governmental Entity , Antitrust Laws , Specified Jurisdiction , Antitrust Law , Strongbridge Options , Strongbridge Warrants , Strongbridge Convertibles , Benefit Statement , Effective Time , About Strongbridge Biopharma , Strongbridge Share Awards , Strongbridge Option , Strongbridge Rollover Option , Each Strongbridge Rollover Option , Strongbridge Private Placement Warrant , Strongbridge Assumed Warrant , Reference Property , Strongbridge Assumed Warrants , Strongbridge Assumed , Business Day , Expenses Reimbursement Agreement , Strongbridge Change , End Date , Strongbridge Alternative Proposal , Strongbridge Board , Expenses Reimbursement , Strongbridge Independent Directors , Restricted Share , Takeover Rules , Strongbridge Restricted Share Unit , Strongbridge Share Option , Strongbridge Warrant , Restricted Stock , Convertible Senior Notes , Xeris Stock Option , Xeris Restricted Stock Unit , Xeris Warrant , Xeris Convertible Notes , Xeris Restricted Stock Units , Xeris Stock Options , Xeris Warrants , Irish Companies Act , Takeover Panel Act , Sherman Act , Clayton Act , Federal Trade Commission Act , Caxton Alternative Management , Council Regulation , Takeover Offer Documents , Strongbridge Memorandum , United States Securities Exchange Act , United States Food , Federal Food , Cosmetic Act , Northern Ireland , Irish Takeover Panel Act , Strongbridge Equity Award Holders , Strongbridge Warrant Holders , Strongbridge Convertible Holder , United States Securities , United States Securities Act , Concert Parties , Strongbridge Loan Agreement , Equity Award ,